200 related articles for article (PubMed ID: 10781666)
1. Changes in rat brain energetic metabolism after exposure to anandamide or Delta(9)-tetrahydrocannabinol.
Costa B; Colleoni M
Eur J Pharmacol; 2000 Apr; 395(1):1-7. PubMed ID: 10781666
[TBL] [Abstract][Full Text] [Related]
2. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors.
Wagner JA; Járai Z; Bátkai S; Kunos G
Eur J Pharmacol; 2001 Jul; 423(2-3):203-10. PubMed ID: 11448486
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological characterisation of cannabinoid CB(1) receptors in the rat and mouse.
Lay L; Angus JA; Wright CE
Eur J Pharmacol; 2000 Mar; 391(1-2):151-61. PubMed ID: 10720647
[TBL] [Abstract][Full Text] [Related]
4. Anandamide- and delta9-tetrahydrocannabinol-evoked arachidonic acid mobilization and blockade by SR141716A [N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4 -methyl-1H-pyrazole-3-carboximide hydrochloride].
Shivachar AC; Martin BR; Ellis EF
Biochem Pharmacol; 1996 Mar; 51(5):669-76. PubMed ID: 8615904
[TBL] [Abstract][Full Text] [Related]
5. Cannabinoid-induced changes in respiration of brain mitochondria.
Fišar Z; Singh N; Hroudová J
Toxicol Lett; 2014 Nov; 231(1):62-71. PubMed ID: 25195527
[TBL] [Abstract][Full Text] [Related]
6. The cannabinoid CB1 receptor antagonist SR141716A attenuates the memory impairment produced by delta9-tetrahydrocannabinol or anandamide.
Mallet PE; Beninger RJ
Psychopharmacology (Berl); 1998 Nov; 140(1):11-9. PubMed ID: 9862397
[TBL] [Abstract][Full Text] [Related]
7. Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats.
Smith FL; Fujimori K; Lowe J; Welch SP
Pharmacol Biochem Behav; 1998 May; 60(1):183-91. PubMed ID: 9610941
[TBL] [Abstract][Full Text] [Related]
8. Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to delta 9-tetrahydrocannabinol.
Romero J; García L; Fernández-Ruiz JJ; Cebeira M; Ramos JA
Pharmacol Biochem Behav; 1995 Aug; 51(4):731-7. PubMed ID: 7675852
[TBL] [Abstract][Full Text] [Related]
9. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding.
Gómez R; Navarro M; Ferrer B; Trigo JM; Bilbao A; Del Arco I; Cippitelli A; Nava F; Piomelli D; Rodríguez de Fonseca F
J Neurosci; 2002 Nov; 22(21):9612-7. PubMed ID: 12417686
[TBL] [Abstract][Full Text] [Related]
10. Mesenteric vasodilation mediated by endothelial anandamide receptors.
Wagner JA; Varga K; Járai Z; Kunos G
Hypertension; 1999 Jan; 33(1 Pt 2):429-34. PubMed ID: 9931142
[TBL] [Abstract][Full Text] [Related]
11. Loss of cannabinoid-stimulated guanosine 5'-O-(3-[(35)S]Thiotriphosphate) binding without receptor down-regulation in brain regions of anandamide-tolerant rats.
Rubino T; Viganò D; Costa B; Colleoni M; Parolaro D
J Neurochem; 2000 Dec; 75(6):2478-84. PubMed ID: 11080200
[TBL] [Abstract][Full Text] [Related]
12. The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by delta(9)-tetrahydrocannabinol and other cannnabinoids.
Darmani NA
J Pharmacol Exp Ther; 2002 Jan; 300(1):34-42. PubMed ID: 11752094
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors.
Hough LB; Nalwalk JW; Stadel R; Timmerman H; Leurs R; Paria BC; Wang X; Dey SK
J Pharmacol Exp Ther; 2002 Oct; 303(1):314-22. PubMed ID: 12235266
[TBL] [Abstract][Full Text] [Related]
14. Apparent affinity estimates of rimonabant in combination with anandamide and chemical analogs of anandamide in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
McMahon LR
Psychopharmacology (Berl); 2009 Apr; 203(2):219-28. PubMed ID: 18592221
[TBL] [Abstract][Full Text] [Related]
15. Cannabinoid influences on palatability: microstructural analysis of sucrose drinking after delta(9)-tetrahydrocannabinol, anandamide, 2-arachidonoyl glycerol and SR141716.
Higgs S; Williams CM; Kirkham TC
Psychopharmacology (Berl); 2003 Feb; 165(4):370-7. PubMed ID: 12447606
[TBL] [Abstract][Full Text] [Related]
16. Behavioral and molecular changes elicited by acute administration of SR141716 to Delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence.
González S; Fernández-Ruiz J; Di Marzo V; Hernández M; Arévalo C; Nicanor C; Cascio MG; Ambrosio E; Ramos JA
Drug Alcohol Depend; 2004 May; 74(2):159-70. PubMed ID: 15099659
[TBL] [Abstract][Full Text] [Related]
17. Effects of SR 141716A after acute or chronic cannabinoid administration in dogs.
Lichtman AH; Wiley JL; LaVecchia KL; Neviaser ST; Arthur DB; Wilson DM; Martin BR
Eur J Pharmacol; 1998 Sep; 357(2-3):139-48. PubMed ID: 9797029
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the discriminative stimulus effects of delta(9)-tetrahydrocannabinol and O-1812, a potent and metabolically stable anandamide analog, in rats.
Wiley JL; LaVecchia KL; Karp NE; Kulasegram S; Mahadevan A; Razdan RK; Martin BR
Exp Clin Psychopharmacol; 2004 Aug; 12(3):173-9. PubMed ID: 15301634
[TBL] [Abstract][Full Text] [Related]
19. Critical role of the endogenous cannabinoid system in mouse pup suckling and growth.
Fride E; Ginzburg Y; Breuer A; Bisogno T; Di Marzo V; Mechoulam R
Eur J Pharmacol; 2001 May; 419(2-3):207-14. PubMed ID: 11426843
[TBL] [Abstract][Full Text] [Related]
20. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors.
Williams CM; Kirkham TC
Psychopharmacology (Berl); 1999 Apr; 143(3):315-7. PubMed ID: 10353436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]